The estimated Net Worth of Pioneer Pharma Holdings Ltd... is at least $291 Tisíc dollars as of 13 May 2014. Pioneer Ltd owns over 65,065 units of Novabay Pharmaceuticals Inc stock worth over $291,489 and over the last 11 years Pioneer sold NBY stock worth over $0.
Pioneer has made over 5 trades of the Novabay Pharmaceuticals Inc stock since 2013, according to the Form 4 filled with the SEC. Most recently Pioneer bought 65,065 units of NBY stock worth $64,414 on 13 May 2014.
The largest trade Pioneer's ever made was buying 5,000,000 units of Novabay Pharmaceuticals Inc stock on 2 December 2013 worth over $5,700,000. On average, Pioneer trades about 1,121,631 units every 59 days since 2013. As of 13 May 2014 Pioneer still owns at least 608,156 units of Novabay Pharmaceuticals Inc stock.
You can see the complete history of Pioneer Ltd stock trades at the bottom of the page.
Pioneer's mailing address filed with the SEC is 190 ELGIN AVENUE, GEORGE TOWN,, , GRAND CAYMAN, E9, KY1-9005.
Over the last 18 years, insiders at Novabay Pharmaceuticals Inc have traded over $3,799,939 worth of Novabay Pharmaceuticals Inc stock and bought 24,568,662 units worth $26,237,091 . The most active insiders traders include Pharma (Singapore) Pte. Ltd..., Pioneer Pharma Holdings Ltd... a Pharma (Hong Kong) Co Ltd P.... On average, Novabay Pharmaceuticals Inc executives and independent directors trade stock every 57 days with the average trade being worth of $127,779. The most recent stock trade was executed by Paul E. Freiman on 11 May 2023, trading 858 units of NBY stock currently worth $411.
novabay pharmaceuticals $nby is a biopharmaceutical company focusing, commercializing and developing its non-antibiotic anti-infective products to address the unmet therapeutic needs of the global eye care market. novabay has two distinct product categories: the neutrox™ family of products, led by avenova™ for the eye care market, neutrophase® for wound care, and cellerx™ for the dermatology market; and aganocide® compounds, led by auriclosene™. novabay is commercializing avenova, a prescription lid and lash hygiene product for the management of the chronic eye conditions of blepharitis and meibomian gland dysfunction – also known as dry eye syndrome. these difficult-to-manage conditions affect approximately 30 million americans, with an annual market potential that novabay estimates at $500 million. novabay is gaining market traction with avenova through its 35-medical direct sales representatives under veteran leadership. avenova is available for order in 90% of all pharmacies across
Novabay Pharmaceuticals Inc executives and other stock owners filed with the SEC include: